untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:32:25Z</responseDate>
<request identifier=oai:HAL:inserm-00903890v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:inserm-00903890v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:INSERM</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana.</title>
<creator>Nacher, Mathieu</creator>
<creator>Stefani, Aurelia</creator>
<creator>Basurko, Celia</creator>
<creator>Lemonnier, Delphine</creator>
<creator>Djossou, Félix</creator>
<creator>Demar, Magalie</creator>
<creator>Elenga, Narcisse</creator>
<creator>Brousse, Paul</creator>
<creator>Ville, Muriel</creator>
<creator>Carme, Bernard</creator>
<contributor>Epidémiologie des parasitoses et mycoses tropicales ; Université des Antilles et de la Guyane (UAG) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Centre d'investigation clinique Antilles-Guyane ; Institut National de la Santé et de la Recherche Médicale (INSERM) - CH Cayenne</contributor>
<contributor>Pharmacie Centrale ; Centre Hospitalier de Cayenne Andrée Rosemon</contributor>
<contributor>Unité des Maladies Infectieuses et Tropicales ; Centre Hospitalier de Cayenne Andrée Rosemon</contributor>
<contributor>Service de Pédiatrie ; Centre Hospitalier de Cayenne Andrée Rosemon</contributor>
<contributor>Département des Centres Délocalisés de Prévention et de Soins ; Centre Hospitalier de Cayenne Andrée Rosemon</contributor>
<contributor>Laboratoire Hospitalo-Universitaire de Parasitologie-Mycologie ; Centre Hospitalier de Cayenne Andrée Rosemon - Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)</contributor>
<description>International audience</description>
<source>ISSN: 1475-2875</source>
<source>Malaria Journal</source>
<publisher>BioMed Central</publisher>
<identifier>inserm-00903890</identifier>
<identifier>http://www.hal.inserm.fr/inserm-00903890</identifier>
<identifier>http://www.hal.inserm.fr/inserm-00903890/document</identifier>
<identifier>http://www.hal.inserm.fr/inserm-00903890/file/1475-2875-12-367.pdf</identifier>
<source>http://www.hal.inserm.fr/inserm-00903890</source>
<source>Malaria Journal, BioMed Central, 2013, 12 (1), pp.367. 〈10.1186/1475-2875-12-367〉</source>
<identifier>DOI : 10.1186/1475-2875-12-367</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/1475-2875-12-367</relation>
<identifier>PUBMED : 24156660</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/24156660</relation>
<language>en</language>
<subject>[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>: Malaria is a public health problem in French Guiana. Plasmodium vivax is the most frequent parasite. The objective of this analysis was to estimate the proportion of relapses in the burden of vivax malaria using the statistical rule stating that any case of vivax malaria occurring less than 90 days following a first episode is a relapse.A total of 622 subjects were followed for 2,9 years with 336 first single episodes of P. vivax malaria, and a total of 1,226 episodes of vivax malaria among which 559 were relapses (45.5%). For 194 patients having had falciparum malaria followed by vivax malaria it was estimated that 19% of the vivax episodes occurred less than 90 days following the falciparum episode and thus were possibly relapses due to the activation of latent hypnozoites. Despite the number of vivax cases and the number of relapses, there were only 28 recorded primaquine prescriptions (3.4% of vivax episodes, 4.5% of subjects).The present study points out that despite the fact that nearly half of the P. vivax cases, many of which in children, are caused by latent hypnozoites, only a minority of them benefit from primaquine radical cure. The obstacles to this are discussed and suggestions are made to reduce the burden of vivax malaria in Camopi and other remote health centres in French Guiana.</description>
<date>2013-10-24</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
